More moderate, but not negative

01/04/20 -"Our view on Symrise has not fundamentally changed but we believe the business will not be fully disconnected from the global economic crises triggered by the COVID-19 pandemic. Therefore, we have ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

01/04/20

Download

You may also be interested by these reports :

23/04/24

AkzoNobel

Akzo’s Q1 delivered a strong set of consensus-beating figures (sales: +1.9%; adjusted EBITDA: +4.3%; net profit: +23.4%). After all the past trouble ...

22/04/24

Brenntag

Downgrade to Add – New target price EUR 85

19/04/24

Gurit

Disappointing on first sight, but well in-line with our investment case on second glance

16/04/24

Clariant

Supporting fundamentals & no more Kottmann items

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue